Bent bone dysplasia syndrome reveals nucleolar activity for FGFR2 in ribosomal DNA transcription

Human Molecular Genetics

Volumn 23, Issue 21, 2014, Pages 5659-5671

  Neben, Cynthia L ^a,b   Idoni, Brian ^a   Salva, Joanna E ^a,b   Tuzon, Creighton T ^b   Rice, Judd C ^b   Krakow, Deborah ^c   Merrill, Amy E ^a,b  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FIBROBLAST GROWTH FACTOR 2; FIBROBLAST GROWTH FACTOR RECEPTOR 2; KARYOPHERIN BETA; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN; RIBOSOME DNA; STAT PROTEIN; TRANSCRIPTION FACTOR RUNX2; UBF1 PROTEIN; UNCLASSIFIED DRUG; PROTEIN BINDING; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR UBF;

ARTICLE; BENT BONE DYSPLASIA SYNDROME; BONE DEFECT; BONE DYSPLASIA; CELL DIFFERENTIATION; CELL MEMBRANE; CELL PROLIFERATION; CELLULAR DISTRIBUTION; CHROMATIN IMMUNOPRECIPITATION; DNA TRANSCRIPTION; HUMAN; IMMUNOPRECIPITATION; MITOGENESIS; MUTATION; OSTEOBLAST; OSTEOPROGENITOR CELL; PROMOTER REGION; PROTEIN BINDING; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; WESTERN BLOTTING; ACROCEPHALOSYNDACTYLY; ANIMAL; BINDING SITE; CELL LINE; CELL NUCLEUS; CYTOLOGY; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; GENETICS; METABOLISM; MOUSE; NUCLEOTIDE REPEAT; PROTEIN TRANSPORT;

ACROCEPHALOSYNDACTYLIA; ANIMALS; BINDING SITES; CELL DIFFERENTIATION; CELL LINE; CELL NUCLEUS; CORE BINDING FACTOR ALPHA 1 SUBUNIT; DNA, RIBOSOMAL; FIBROBLAST GROWTH FACTOR 2; GENE EXPRESSION REGULATION; HUMANS; MAP KINASE SIGNALING SYSTEM; MICE; MUTATION; OSTEOBLASTS; POL1 TRANSCRIPTION INITIATION COMPLEX PROTEINS; PROTEIN BINDING; PROTEIN TRANSPORT; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 2; REPETITIVE SEQUENCES, NUCLEIC ACID; TRANSCRIPTION, GENETIC;

EID: 84911392819     PISSN: 09646906     EISSN: 14602083     Source Type: Journal    
DOI: 10.1093/hmg/ddu282     Document Type: Article

References (49)

1. Stoll, C., Dott, B., Roth, M.P. and Alembik, Y. (1989) Birth prevalence rates of skeletal dysplasias. Clin. Genet., 35, 88-92.
2. Wilkie, A.O. (2005) Bad bones, absent smell, selfish testes: the pleiotropic consequences of human FGF receptor mutations. Cytokine Growth Factor Rev., 16, 187-203.
3. Lew, E.D., Bae, J.H., Rohmann, E., Wollnik, B. and Schlessinger, J. (2007) Structural basis for reduced FGFR2 activity in LADD syndrome: Implications for FGFR autoinhibition and activation. Proc. Natl. Acad. Sci. USA, 104, 19802-19807.
4. Eswarakumar, V.P., Horowitz, M.C., Locklin, R., Morriss-Kay, G.M. and Lonai, P. (2004) A gain-of-function mutation of Fgfr2c demonstrates the roles of this receptor variant in osteogenesis. Proc. Natl. Acad. Sci. USA, 101, 12555-12560.
5. Wang, Y., Xiao, R., Yang, F., Karim, B.O., Iacovelli, A.J., Cai, J., Lerner, C.P., Richtsmeier, J.T., Leszl, J.M., Hill, C.A. et al. (2005) Abnormalities in cartilage and bone development in the Apert syndrome FGFR2(+/S252W) mouse. Development, 132, 3537-3548.
6. Yu, K., Xu, J., Liu, Z., Sosic, D., Shao, J., Olson, E.N., Towler, D.A. and Ornitz, D.M. (2003) Conditional inactivation of FGF receptor 2 reveals an essential role for FGF signaling in the regulation of osteoblast function and bone growth. Development, 130, 3063-3074.
7. Eswarakumar, V.P., Monsonego-Ornan, E., Pines, M., Antonopoulou, I., Morriss-Kay, G.M. and Lonai, P. (2002) The IIIc alternative of Fgfr2 is a positive regulator of bone formation. Development, 129, 3783-3793.
8. Moore, R., Ferretti, P., Copp, A. and Thorogood, P. (2002) Blocking endogenous FGF-2 activity prevents cranial osteogenesis. Dev. Biol., 243, 99-114.
9. Ohbayashi, N., Shibayama, M., Kurotaki, Y., Imanishi, M., Fujimori, T., Itoh,N. and Takada, S. (2002)FGF18is required for normal cell proliferation and differentiation during osteogenesis and chondrogenesis. Genes Dev., 16, 870-879.
10. Kim, B.G., Kim, H.J., Park, H.J., Kim, Y.J., Yoon, W.J., Lee, S.J., Ryoo, H.M. and Cho, J.Y. (2006) Runx2 phosphorylation induced by fibroblast growth factor-2/protein kinase C pathways. Proteomics, 6, 1166-1174.
11. Miraoui, H., Oudina, K., Petite, H., Tanimoto, Y., Moriyama, K. and Marie, P.J. (2009) Fibroblast growth factor receptor 2 promotes osteogenic differentiation in mesenchymal cells via ERK1/2 and protein kinase C signaling. J. Biol. Chem., 284, 4897-4904.
12. Xiao, G., Jiang, D., Gopalakrishnan, R. and Franceschi, R.T. (2002) Fibroblast growth factor 2 induction of the osteocalcin gene requiresMAPK activity and phosphorylation of the osteoblast transcription factor, Cbfa1/ Runx2. J. Biol. Chem., 277, 36181-36187.
13. Dailey, L., Ambrosetti, D., Mansukhani, A. and Basilico, C. (2005) Mechanisms underlying differential responses to FGF signaling. Cytokine Growth Factor Rev., 16, 233-247.
14. Sorensen, V., Nilsen, T. and Wiedlocha, A. (2006) Functional diversity of FGF-2 isoforms by intracellular sorting. Bioessays, 28, 504-514.
15. Arese, M., Chen, Y., Florkiewicz, R.Z., Gualandris, A., Shen, B. and Rifkin, D.B. (1999) Nuclear activities of basic fibroblast growth factor: potentiation of low-serum growth mediated by natural or chimeric nuclear localization signals. Mol. Biol. Cell, 10, 1429-1444.
16. Reilly, J.F. and Maher, P.A. (2001) Importin beta-mediated nuclear import of fibroblast growth factor receptor: role in cell proliferation. J. Cell Biol., 152, 1307-1312.
17. Stachowiak, M.K., Maher, P.A. and Stachowiak, E.K. (2007) Integrative nuclear signaling in cell development - a role for FGF receptor-1. DNA Cell Biol., 26, 811-826.
18. Merrill, A.E., Sarukhanov, A., Krejci, P., Idoni, B., Camacho, N., Estrada, K.D., Lyons, K.M., Deixler, H., Robinson, H., Chitayat, D. et al. (2012) Bent bone dysplasia-FGFR2 type, a distinct skeletal disorder, has deficient canonical FGF signaling. Am. J. Hum. Genet., 90, 550-557.
19. Bouche, G., Gas, N., Prats, H., Baldin, V., Tauber, J.P., Teissie, J. and Amalric, F. (1987) Basic fibroblast growth factor enters the nucleolus and stimulates the transcription of ribosomal genes in ABAE cells undergoing G0 - G1 transition. Proc. Natl. Acad. Sci. USA, 84, 6770-6774.
20. Sheng, Z., Liang, Y., Lin, C.Y., Comai, L. and Chirico, W.J. (2005) Direct regulation of rRNA transcription by fibroblast growth factor 2. Mol. Cell. Biol., 25, 9419-9426.
21. Hisaoka, M., Ueshima, S., Murano, K., Nagata, K. and Okuwaki, M. (2010) Regulation of nucleolar chromatin by B23/nucleophosmin jointly depends upon itsRNAbinding activity and transcription factor UBF. Mol. Cell. Biol., 30, 4952-4964.
22. Wiedlocha, A., Falnes, P.O., Madshus, I.H., Sandvig, K. and Olsnes, S. (1994) Dual mode of signal transduction by externally added acidic fibroblast growth factor. Cell, 76, 1039-1051.
23. Gaubert, F., Escaffit, F., Bertrand, C., Korc, M., Pradayrol, L., Clemente, F. and Estival, A. (2001) Expression of the high molecular weight fibroblast growth factor-2 isoform of 210 amino acids is associated with modulation of protein kinases C delta and epsilon and ERK activation. J. Biol. Chem., 276, 1545-1554.
24. Lechertier, T., Sirri, V., Hernandez-Verdun, D. and Roussel, P. (2007) A B23-interacting sequence as a tool to visualize protein interactions in a cellular context. J. Cell Sci., 120, 265-275.
25. Moss, T., Stefanovsky, V., Langlois, F. andGagnon-Kugler, T. (2006)Anew paradigm for the regulation of the mammalian ribosomal RNA genes. Biochem. Soc. Trans., 34, 1079-1081.
26. Grummt, I. (1999) Regulation of mammalian ribosomal gene transcription by RNA polymerase I. Prog. Nucleic Acid Res. Mol. Biol., 62, 109-154.
27. Laferte, A., Favry, E., Sentenac, A., Riva, M., Carles, C. and Chedin, S. (2006)The transcriptional activity ofRNApolymerase I is a key determinant for the level of all ribosome components. Genes Dev., 20, 2030-2040.
28. Montanaro, L., Trere, D. and Derenzini, M. (2008) Nucleolus, ribosomes, and cancer. Am. J. Pathol., 173, 301-310.
29. Budde, A. and Grummt, I. (1999) p53 represses ribosomal gene transcription. Oncogene, 18, 1119-1124.
30. Young, D.W., Hassan, M.Q., Pratap, J., Galindo, M., Zaidi, S.K., Lee, S.H., Yang, X., Xie, R., Javed, A., Underwood, J.M. et al. (2007) Mitotic occupancy and lineage-specific transcriptional control of rRNA genes by Runx2. Nature, 445, 442-446.
31. Liu, Y.H., Tang, Z., Kundu, R.K., Wu, L., Luo, W., Zhu, D., Sangiorgi, F., Snead, M.L. and Maxson, R.E. (1999) Msx2 gene dosage influences the number of proliferative osteogenic cells in growth centers of the developing murine skull: a possible mechanismforMSX2-mediated craniosynostosis in humans. Dev. Biol., 205, 260-274.
32. Satokata, I., Ma, L., Ohshima, H., Bei, M., Woo, I., Nishizawa, K., Maeda, T., Takano, Y., Uchiyama, M., Heaney, S. et al. (2000) Msx2 deficiency in mice causes pleiotropic defects in bone growth and ectodermal organ formation. Nat. Genet., 24, 391-395.
33. Rice, R., Rice, D.P., Olsen, B.R. and Thesleff, I. (2003) Progression of calvarial bone development requires Foxc1 regulation of Msx2 and Alx4. Dev. Biol., 262, 75-87.
34. Lee, B., Thirunavukkarasu, K., Zhou, L., Pastore, L., Baldini, A., Hecht, J., Geoffroy, V., Ducy, P. and Karsenty, G. (1997) Missense mutations abolishing DNA binding of the osteoblast-specific transcription factor OSF2/CBFA1 in cleidocranial dysplasia. Nat. Genet., 16, 307-310.
35. Komori, T., Yagi, H., Nomura, S., Yamaguchi, A., Sasaki, K., Deguchi, K., Shimizu, Y., Bronson, R.T., Gao, Y.H., Inada, M. et al. (1997) Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts. Cell, 89, 755-764.
36. Kim, H.J., Kim, J.H., Bae, S.C., Choi, J.Y., Kim, H.J. and Ryoo, H.M. (2003) The protein kinase C pathway plays a central role in the fibroblast growth factor-stimulated expression and transactivation activity of Runx2. J. Biol. Chem., 278, 319-326.
37. Park, O.J., Kim, H.J., Woo, K.M., Baek, J.H. and Ryoo, H.M. (2010) FGF2-activated ERK mitogen-activated protein kinase enhances Runx2 acetylation and stabilization. J. Biol. Chem., 285, 3568-3574.
38. Ducy, P. and Karsenty, G. (1995) Two distinct osteoblast-specific cis-acting elements control expression of amouse osteocalcin gene. Mol. Cell. Biol., 15, 1858-1869.
39. Schmahl, J., Kim, Y., Colvin, J.S., Ornitz, D.M. and Capel, B. (2004) Fgf9 induces proliferation and nuclear localization of FGFR2 in Sertoli precursors during male sex determination. Development, 131, 3627- 3636.
40. Hannan, K.M., Sanij, E., Rothblum, L.I., Hannan, R.D. and Pearson, R.B. (2013) Dysregulation of RNA polymerase I transcription during disease. Biochim. Biophys. Acta, 1829, 342-360.
41. Pollock, P.M., Gartside, M.G., Dejeza, L.C., Powell, M.A., Mallon, M.A., Davies, H., Mohammadi, M., Futreal, P.A., Stratton, M.R., Trent, J.M. et al. (2007) Frequent activating FGFR2 mutations in endometrial carcinomas parallel germline mutations associated with craniosynostosis and skeletal dysplasia syndromes. Oncogene, 26, 7158-7162.
42. Ruggero, D. and Pandolfi, P.P. (2003) Does the ribosome translate cancer? Nat. Rev. Cancer, 3, 179-192.
43. Turner, N. and Grose, R. (2010) Fibroblast growth factor signalling: from development to cancer. Nat. Rev. Cancer, 10, 116-129.
44. Amalric, F., Bouche, G., Bonnet, H., Brethenou, P., Roman, A.M., Truchet, I. and Quarto, N. (1994) Fibroblast growth factor-2 (FGF-2) in the nucleus: translocation process and targets. Biochem. Pharmacol., 47, 111-115.
45. Sosnowski, B.A., Gonzalez, A.M., Chandler, L.A., Buechler, Y.J., Pierce, G.F. and Baird, A. (1996) Targeting DNA to cells with basic fibroblast growth factor (FGF2). J. Biol. Chem., 271, 33647-33653.
46. Bakker, A.D. and Klein-Nulend, J. (2012) Osteoblast isolation from murine calvaria and long bones. Methods Mol. Biol., 816, 19-29.
47. Fouletier-Dilling, C.M., Bosch, P., Davis, A.R., Shafer, J.A., Stice, S.L., Gugala, Z., Gannon, F.H. and Olmsted-Davis, E.A. (2005) Novel compound enables high-level adenovirus transduction in the absence of an adenovirus-specific receptor. Hum. Gene Ther., 16, 1287-1297.
48. Busch, H., Muramatsu, M., Adams, H., Steele, W.J., Liau, M.C. and Smetana, K. (1963) Isolation of nucleoli. Exp. Cell Res., 24(Suppl. 9), 150-163.
49. Drygin, D., Lin, A., Bliesath, J., Ho, C.B., O'Brien, S.E., Proffitt, C., Omori, M., Haddach, M., Schwaebe, M.K., Siddiqui-Jain, A. et al. (2011) Targeting RNA polymerase I with an oral small molecule CX-5461 inhibits ribosomal RNA synthesis and solid tumor growth. Cancer Res., 71, 1418-1430.